90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies
Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators...
Gespeichert in:
| Veröffentlicht in: | Journal of molecular endocrinology 2020-07, Vol.65 (1), p.T15-T33 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | T33 |
|---|---|
| container_issue | 1 |
| container_start_page | T15 |
| container_title | Journal of molecular endocrinology |
| container_volume | 65 |
| creator | Critchley, H O D Chodankar, R R |
| description | Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women’s quality of life. |
| doi_str_mv | 10.1530/JME-19-0238 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7354704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2435212408</sourcerecordid><originalsourceid>FETCH-LOGICAL-b381t-b989bd3cc3c2ddc0f099340e8d093fec125b42b88f6cbf3b3c3dedfcb2b5a1123</originalsourceid><addsrcrecordid>eNp9kc9rFDEUx4Modq2evEvAiyCj-TmbeBBKmValurJbD55iknmzTZmdjMlMof-9WbYW9eDpPXgfvny_74vQc0reUMnJ20-fm4rqijCuHqAFFUtd1Yryh2hBtGSVJIIeoSc5XxNCJV2Kx-iIM6m1rOUC_dAEf29O1hu8OsNf16vzZnPZrFdfmnd4Az34KdwAHlPcQp4gxQFwAg_jFBPexXbubdkyDgPe3g4WfOzjNnjb4-kKkh0D5KfoUWf7DM_u5jH6dtZcnn6oLlbnH09PLirHFZ0qp5V2Lfeee9a2nnREay4IqJZo3oGnTDrBnFJd7V3HHfe8hbbzjjlpKWX8GL0_6I6z20HrYZiS7c2Yws6mWxNtMH9fhnBltvHGLLkUSyKKwKs7gRR_ziWu2YXsoe_tAHHOhgmqiapZrQr68h_0Os5pKPEKxSWjTJA99fpA-RRzTtDdm6HE7JszpTlDtdk3V-gXf_q_Z39XVQB6AFyI2YeSInTl1f8V_QVaMaSp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435212408</pqid></control><display><type>article</type><title>90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Society for Endocrinology Journals</source><creator>Critchley, H O D ; Chodankar, R R</creator><creatorcontrib>Critchley, H O D ; Chodankar, R R</creatorcontrib><description>Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women’s quality of life.</description><identifier>ISSN: 0952-5041</identifier><identifier>ISSN: 1479-6813</identifier><identifier>EISSN: 1479-6813</identifier><identifier>DOI: 10.1530/JME-19-0238</identifier><identifier>PMID: 32599565</identifier><language>eng</language><publisher>England: Bioscientifica Ltd</publisher><subject>Acetic acid ; Clinical Trials as Topic ; Contraception ; Female ; Fertility ; Fibroids ; Genital Diseases, Female - drug therapy ; Genital Diseases, Female - metabolism ; Gynecology ; Humans ; Mifepristone ; Pregnancy ; Progesterone ; Progesterone - metabolism ; Progesterone Congeners - chemistry ; Progesterone Congeners - pharmacology ; Progesterone Congeners - therapeutic use ; Quality of life ; Receptors, Progesterone - metabolism ; Reproductive health ; Thematic Review ; Uterus ; Womens health</subject><ispartof>Journal of molecular endocrinology, 2020-07, Vol.65 (1), p.T15-T33</ispartof><rights>2020 The authors</rights><rights>Copyright Society for Endocrinology & BioScientifica Ltd. Jul 2020</rights><rights>2020 The authors 2020 The authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b381t-b989bd3cc3c2ddc0f099340e8d093fec125b42b88f6cbf3b3c3dedfcb2b5a1123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3936,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32599565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Critchley, H O D</creatorcontrib><creatorcontrib>Chodankar, R R</creatorcontrib><title>90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies</title><title>Journal of molecular endocrinology</title><addtitle>J Mol Endocrinol</addtitle><description>Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women’s quality of life.</description><subject>Acetic acid</subject><subject>Clinical Trials as Topic</subject><subject>Contraception</subject><subject>Female</subject><subject>Fertility</subject><subject>Fibroids</subject><subject>Genital Diseases, Female - drug therapy</subject><subject>Genital Diseases, Female - metabolism</subject><subject>Gynecology</subject><subject>Humans</subject><subject>Mifepristone</subject><subject>Pregnancy</subject><subject>Progesterone</subject><subject>Progesterone - metabolism</subject><subject>Progesterone Congeners - chemistry</subject><subject>Progesterone Congeners - pharmacology</subject><subject>Progesterone Congeners - therapeutic use</subject><subject>Quality of life</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Reproductive health</subject><subject>Thematic Review</subject><subject>Uterus</subject><subject>Womens health</subject><issn>0952-5041</issn><issn>1479-6813</issn><issn>1479-6813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9rFDEUx4Modq2evEvAiyCj-TmbeBBKmValurJbD55iknmzTZmdjMlMof-9WbYW9eDpPXgfvny_74vQc0reUMnJ20-fm4rqijCuHqAFFUtd1Yryh2hBtGSVJIIeoSc5XxNCJV2Kx-iIM6m1rOUC_dAEf29O1hu8OsNf16vzZnPZrFdfmnd4Az34KdwAHlPcQp4gxQFwAg_jFBPexXbubdkyDgPe3g4WfOzjNnjb4-kKkh0D5KfoUWf7DM_u5jH6dtZcnn6oLlbnH09PLirHFZ0qp5V2Lfeee9a2nnREay4IqJZo3oGnTDrBnFJd7V3HHfe8hbbzjjlpKWX8GL0_6I6z20HrYZiS7c2Yws6mWxNtMH9fhnBltvHGLLkUSyKKwKs7gRR_ziWu2YXsoe_tAHHOhgmqiapZrQr68h_0Os5pKPEKxSWjTJA99fpA-RRzTtDdm6HE7JszpTlDtdk3V-gXf_q_Z39XVQB6AFyI2YeSInTl1f8V_QVaMaSp</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Critchley, H O D</creator><creator>Chodankar, R R</creator><general>Bioscientifica Ltd</general><general>Society for Endocrinology & BioScientifica Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200701</creationdate><title>90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies</title><author>Critchley, H O D ; Chodankar, R R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b381t-b989bd3cc3c2ddc0f099340e8d093fec125b42b88f6cbf3b3c3dedfcb2b5a1123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetic acid</topic><topic>Clinical Trials as Topic</topic><topic>Contraception</topic><topic>Female</topic><topic>Fertility</topic><topic>Fibroids</topic><topic>Genital Diseases, Female - drug therapy</topic><topic>Genital Diseases, Female - metabolism</topic><topic>Gynecology</topic><topic>Humans</topic><topic>Mifepristone</topic><topic>Pregnancy</topic><topic>Progesterone</topic><topic>Progesterone - metabolism</topic><topic>Progesterone Congeners - chemistry</topic><topic>Progesterone Congeners - pharmacology</topic><topic>Progesterone Congeners - therapeutic use</topic><topic>Quality of life</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Reproductive health</topic><topic>Thematic Review</topic><topic>Uterus</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Critchley, H O D</creatorcontrib><creatorcontrib>Chodankar, R R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of molecular endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Critchley, H O D</au><au>Chodankar, R R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies</atitle><jtitle>Journal of molecular endocrinology</jtitle><addtitle>J Mol Endocrinol</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>65</volume><issue>1</issue><spage>T15</spage><epage>T33</epage><pages>T15-T33</pages><issn>0952-5041</issn><issn>1479-6813</issn><eissn>1479-6813</eissn><abstract>Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women’s quality of life.</abstract><cop>England</cop><pub>Bioscientifica Ltd</pub><pmid>32599565</pmid><doi>10.1530/JME-19-0238</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-5041 |
| ispartof | Journal of molecular endocrinology, 2020-07, Vol.65 (1), p.T15-T33 |
| issn | 0952-5041 1479-6813 1479-6813 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7354704 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Society for Endocrinology Journals |
| subjects | Acetic acid Clinical Trials as Topic Contraception Female Fertility Fibroids Genital Diseases, Female - drug therapy Genital Diseases, Female - metabolism Gynecology Humans Mifepristone Pregnancy Progesterone Progesterone - metabolism Progesterone Congeners - chemistry Progesterone Congeners - pharmacology Progesterone Congeners - therapeutic use Quality of life Receptors, Progesterone - metabolism Reproductive health Thematic Review Uterus Womens health |
| title | 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A07%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=90%20YEARS%20OF%20PROGESTERONE:%20Selective%20progesterone%20receptor%20modulators%20in%20gynaecological%20therapies&rft.jtitle=Journal%20of%20molecular%20endocrinology&rft.au=Critchley,%20H%20O%20D&rft.date=2020-07-01&rft.volume=65&rft.issue=1&rft.spage=T15&rft.epage=T33&rft.pages=T15-T33&rft.issn=0952-5041&rft.eissn=1479-6813&rft_id=info:doi/10.1530/JME-19-0238&rft_dat=%3Cproquest_pubme%3E2435212408%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435212408&rft_id=info:pmid/32599565&rfr_iscdi=true |